公开(公告)号：US20240400703A1

公开(公告)日：2024-12-05

申请号：US18660847

申请日：2024-05-10

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Kristel Kemper ,  Maarten van der Kroef ,  Dennis Verzijl ,  Andrea Gorlani ,  Pauline Linda de Goeje ,  Lars Guelen ,  David Satijn ,  Esther C. W. Breij ,  Ugur Sahin ,  Sina Fellermeier-Kopf ,  Maren Köhne

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US11459395B2

公开(公告)日：2022-10-04

申请号：US17172694

申请日：2021-02-10

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Ugur Sahin ,  Friederike Gieseke ,  Alexander Muik ,  Christian Grunwitz ,  Edward Van den Brink ,  Dennis Verzijl

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US10968280B2

公开(公告)日：2021-04-06

申请号：US16779011

申请日：2020-01-31

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Ugur Sahin ,  Friederike Gieseke ,  Alexander Muik ,  Christian Grunwitz

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US20200079866A1

公开(公告)日：2020-03-12

申请号：US16582534

申请日：2019-09-25

Applicant: BIONTECH SE ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US20240254249A1

公开(公告)日：2024-08-01

申请号：US18481578

申请日：2023-10-05

Applicant: BIONTECH SE ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

CPC classification number: C07K16/2878 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US11932693B2

公开(公告)日：2024-03-19

申请号：US18315686

申请日：2023-05-11

Applicant: BioNTech SE ,  Genmab A/S

Inventor： Ugur Sahin ,  Sina Fellermeier-Kopf ,  Friederike Gieseke ,  Karsten Beckmann ,  Claudia Paulmann ,  Alexander Muik ,  Ivan Kuzmanov ,  Esther Cornelia Wilhelmina Breij ,  Patricia Garrido Castro ,  Jordan Blum ,  Lars Guelen ,  Joost Neijssen ,  Bart-Jan De Kreuk ,  Richard Hibbert ,  Janine Schuurman ,  Aran Frank Labrijn

IPC: C07K16/28

CPC classification number: C07K16/2818 ,  C07K2317/24 ,  C07K2317/92

Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.

公开(公告)号：US20210253725A1

公开(公告)日：2021-08-19

申请号：US17144591

申请日：2021-01-08

Applicant: BIONTECH SE ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US11795218B2

公开(公告)日：2023-10-24

申请号：US16795468

申请日：2020-02-19

Applicant: BioNTech AG ,  Ganymed Pharmaceuticals GmbH ,  TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Korden Walter ,  Meike Wagner ,  Maria Kreuzberg ,  Sabine Hacker ,  Stefan Jacobs

IPC: C07K16/28 ,  A61K39/395 ,  A61K31/337 ,  A61K31/5365 ,  A61K31/7048 ,  A61K31/7064 ,  A61K33/243 ,  C07K16/30 ,  A61K47/68 ,  G01N33/574 ,  A61N5/10 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K31/337 ,  A61K31/5365 ,  A61K31/7048 ,  A61K31/7064 ,  A61K33/243 ,  A61K39/39558 ,  A61K47/6851 ,  A61N5/10 ,  C07K16/30 ,  G01N33/57484 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  G01N2333/705 ,  G01N2800/52

Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.

公开(公告)号：US10724103B2

公开(公告)日：2020-07-28

申请号：US15675148

申请日：2017-08-11

Applicant: BioNTech AG

Inventor： Ozlem Tureci ,  Ugur Sahin ,  Sandra Schneider ,  Gerd Helftenbein ,  Volker Schluter ,  Dirk Usener ,  Philippe Thiel ,  Michael Koslowski

IPC: C12Q1/686 ,  C12Q1/6886 ,  C07K14/47 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28 ,  C07K16/30 ,  G01N33/53

Abstract: The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.

公开(公告)号：US10428149B2

公开(公告)日：2019-10-01

申请号：US15558372

申请日：2016-03-18

Applicant: UNIVERSITÄT STUTTGART ,  BIONTECH AG

Inventor： Ugur Sahin ,  Roland Kontermann ,  Klaus Pfizenmaier ,  Martin Siegemund ,  Meike Hutt ,  Oliver Seifert

IPC: C07K16/32 ,  C07K16/28 ,  C07K14/705

Abstract: The present invention relates to a polypeptide comprising a component A with at least three tumor necrosis factor (TNF) homology domains of TNF-ligand family members (THD) in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof, and a component B comprising a dimerization domain. Further, the present invention relates to a polypeptide comprising at least three THDs in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof. Further, the invention relates to a nucleic acid comprising said polypeptides, a vector comprising said nucleic acid and a pharmaceutical composition comprising said polypeptides, or said nucleic acids or said vector. Further, the present invention relates to said polypeptides, said nucleic acid or said vector for the use as a medicament or for the use in the diagnosis, prophylaxis or treatment of hyperproliferative disorders and inflammatory disorders.